In the development, testing, and approval of a new medication, which of the following best describes the question that is being asked in phase 3 testing? Does the medication appear to have a clinical effect when subjected to a double-blind clinical trial? What is the drug's PK in healthy volunteers? What are the results of post-marketing surveillance? How does the medication work in laboratory animals?